Interim response in diffuse large B cell lymphoma on CT: what is the optimal size reduction (ΔSPD) for predicting outcome?

被引:1
作者
Wei, Yun-Chen [1 ,2 ,3 ]
Ding, Chong-Yang [4 ]
Liang, Jin-Hua [1 ,2 ,3 ]
Wang, Li [1 ,2 ,3 ]
Zhu, Hua-Yuan [1 ,2 ,3 ]
Xia, Yi [1 ,2 ,3 ]
Wu, Jia-Zhu [1 ,2 ,3 ]
Fan, Lei [1 ,2 ,3 ]
Li, Tian-Nv [4 ]
Li, Jian-Yong [1 ,2 ,3 ]
Xu, Wei [1 ,2 ,3 ]
机构
[1] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Key Lab Hematol, Nanjing 210029, Peoples R China
[3] Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Peoples R China
[4] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Nucl Med, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
Lymphoma; Prognosis; Positron emission tomography; Computed tomography; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKIN-LYMPHOMA; FDG-PET; RITUXIMAB; CHEMOTHERAPY; SURVIVAL; CRITERIA; CHOP;
D O I
10.1007/s00330-019-06552-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate whether there was an optimal interim size reduction (i Delta SPD) cutoff value that could discriminate diffuse large B cell lymphoma (DLBCL) patients with poor prognosis. Methods This retrospective study enrolled 265 newly diagnosed DLBCL patients with baseline and interim (after 3 cycles) contrast-enhanced computed tomographic scan (CECT) available. Two radiologists evaluated CECT images and selected target lesions according to the Lugano Response Criteria. Lymph nodes greater than 15 mm in longest diameter (LDi) and extra-nodal lesions with LDi greater than 10 mm could be chosen as target lesions and used to calculate i Delta SPD. A software tool, X-Tile, was used to calculate the optimal i Delta SPD cutoff value to differentiate patients with good vs. poor prognosis. Receiver operating characteristic curve analysis, Cox regression analysis, and Kaplan-Meier analyses were further used to validate the optimal cutoff value. Results The optimal cutoff value of i Delta SPD calculated by X-tile was 80%. Compared with 50% and 100%, 80% cutoff value had the intermediate sensitivity and specificity (57.75% and 86.69% for overall survival (OS), 48.98% and 92.22% for progression-free survival (PFS), respectively), but the maximal Youden index (0.4744 for OS, 0.4120 for PFS, respectively) and areas under the curve (0.737 [0.680, 0.789] for OS). Cox regression analysis also revealed that i Delta SPD < 80% could independently predict an inferior OS and PFS (both p < 0.001) while neither i Delta SPD < 50% nor i Delta SPD = 100% could. Conclusions i Delta SPD with the cutoff value 80% is an independent predictor of PFS and OS for patients with DLBCL. Results suggest that treatment should be modified for patients with i Delta SPD < 80%.
引用
收藏
页码:3094 / 3100
页数:7
相关论文
共 22 条
  • [1] Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011
    Al-Hamadani, Mohammed
    Habermann, Thomas M.
    Cerhan, James R.
    Macon, William R.
    Maurer, Matthew J.
    Go, Ronald S.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (09) : 790 - 795
  • [2] Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis
    Burggraaff, Coreline N.
    de Jong, Antoinette
    Hoekstra, Otto S.
    Hoetjes, Nikie J.
    Nievelstein, Rutger A. J.
    Jansma, Elise P.
    Heymans, Martijn W.
    de Vet, Henrica C. W.
    Zijlstra, Josee M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) : 65 - 79
  • [3] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [4] SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
    Casasnovas, Rene -Olivier
    Meignan, Michel
    Berriolo-Riedinger, Alina
    Bardet, Stephane
    Julian, Anne
    Thieblemont, Catherine
    Vera, Pierre
    Bologna, Serge
    Briere, Josette
    Jais, Jean-Philippe
    Haioun, Corinne
    Coiffier, Bertrand
    Morschhauser, Franck
    [J]. BLOOD, 2011, 118 (01) : 37 - 43
  • [5] 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
    Cashen, Amanda F.
    Dehdashti, Farrokh
    Luo, Jingqin
    Homb, Andrew
    Siegel, Barry A.
    Bartlett, Nancy L.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (03) : 386 - 392
  • [6] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [7] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
    Cheson, Bruce D.
    Fisher, Richard I.
    Barrington, Sally F.
    Cavalli, Franco
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Lister, T. Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3059 - +
  • [8] Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings
    Chow, A.
    Phillips, M.
    Siew, T.
    Cull, G.
    Augustson, B.
    Ward, M.
    Joske, D.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (08) : 932 - 939
  • [9] Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
    Dupuis, J.
    Itti, E.
    Rahmouni, A.
    Hemery, F.
    Gisselbrecht, C.
    Lin, C.
    Copie-Bergman, C.
    Belhadj, K.
    El Gnaoui, T.
    Gaillard, I.
    Kuhnowski, F.
    Meignan, M.
    Haioun, C.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (03) : 503 - 507
  • [10] Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
    Gonzalez-Barca, Eva
    Canales, Miguel
    Cortes, Montse
    Jesus Vidal, M.
    Salar, Antonio
    Oriol, Albert
    Bargay, Joan
    Bello, Jose L.
    Sanchez, Jose J.
    Tomas, Jose F.
    Donato, Eva
    Ferrer, Secundino
    Caballero, Dolores
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2013, 34 (10) : 946 - 952